Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia | Zendy

Gordana MarkovicSovtic | Zendy; Borisav Janković | Zendy; Zorica Rakonjac | Zendy; Jelena Martić | Zendy; Katarina Pejić | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia

Author(s) -

Gordana MarkovicSovtic,

Borisav Janković,

Zorica Rakonjac,

Jelena Martić,

Katarina Pejić

Publication year - 2013

Publication title -

vojnosanitetski pregled

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.123

H-Index - 19

eISSN - 2406-0720

pISSN - 0042-8450

DOI - 10.2298/vsp1311029m

Subject(s) - medicine , antibody , exchange transfusion , adverse effect , neonatal intensive care unit , platelet , immunoglobulin g , intravenous use , hemolytic disease of the newborn (abo) , immune thrombocytopenia , immunology , platelet transfusion , pediatrics , pregnancy , anesthesia , fetus , biology , genetics

Intravenous immunoglobulin is a blood product made of human polyclonal immunoglobulin G. The mode of action of intravenous immunoglobulin is very complex. It is indicated in treatment of neonatal immune thrombocytopenia and haemolytic disease of the newborn. The aim of the study was to present our experience in the use of intravenous immunoglobulin in a group of term neonates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research